PDCD1 and melanoma: This combination was compared to systemic ipilimumab alone in anti-PD-1-refractory, stage III-IVM1c melanoma in a phase 3, randomized trial (NCT03445533); however, it was terminated in 2022 for a lack of improvement in the ORR and OS.